Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Palliative biliary stenting is the principal treatment for unresectable perihilar cholangiocarcinoma (pCCA) patients with jaundice. Endobiliary radiofrequency ablation (EBRFA) is a novel treatment used in combination with biliary stenting for CCA, aiming to prolong stent patency and patient survival. However, the evidence regarding its safety and efficacy in perihilar CCA remains limited. This study aims to investigate the safety of EBRFA and efficacy in terms of increasing stent patency and the patient's survival.
Methods: Patients with unresectable perihilar CCA were prospectively randomized into 2 groups, including EBRFA with self-expandable metallic stent (SEMS) and SEMS alone. Stent patency time was recorded after stent implantation and until obstructive jaundice occurred. The median survival time (MST), median stent patency, and adverse event rate were analyzed and compared using the Log-rank test. The proportion comparisons of patient characteristics, preoperative testing, procedure detail, and morbidity in two methods were conducted by the Chi-square test.
Result: Of a total of 39 patients who were diagnosed with pCCA and included in this study, 22 patients were in the EBRFA group and 17 patients were in the SEMS group. The procedure-related complication rate was not statistically significantly different between the EBRFA and the SEMS groups. There was no statistically significant difference in stent patency time between the EBRFA and SEMS groups (71 vs. 78 days, p-value = 0.809), and the OS of the EBRFA group had no statistically significant difference with the SEMS group (94 vs. 79 days, HR = 1.31, 95%CI: 0.66-2.58, p-value = 0.735).
Conclusion: The EBRFA, when combined with SEMS placement, demonstrated procedural feasibility and acceptable outcomes as a potential palliative approach for patients with unresectable pCCA.
Trial Registration: TCTR20190704002.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232654 | PMC |
| http://dx.doi.org/10.1186/s12876-025-04104-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Cut and Cover": A Case Series of Dual Modality Treatment With Stricturetomy and Stenting for Inflammatory Bowel Disease-Related Strictures.
Cureus
August 2025
Gastroenterology and Hepatology Division of the Department of Internal Medicine, University of Michigan, Ann Arbor, USA.
Strictures are common in inflammatory bowel disease (IBD) and are managed medically and endoscopically, if feasible, due to the risk of surgical complications. While endoscopic balloon dilation (EBD) is often successful, the need for repeat dilation and subsequent surgery is common. Endoscopic stricturotomy (ESt) has gained popularity but has been limited by frequent post-procedural bleeding.
View Article and Find Full Text PDFOne-year outcomes of polymer-free Sirolimus-eluting stents in complex femoropopliteal stenosis: a single center real-world registry.
J Cardiovasc Surg (Torino)
September 2025
Catheterization Laboratory, Montevergine Clinic, Mercogliano, Avellino, Italy -
Background: Lower extremity arterial disease is a prevalent vascular condition leading to ischemic symptoms and increased risk of cardiovascular events. Drug-eluting stents have improved outcomes by reducing restenosis, with sirolimus emerging as a promising alternative to paclitaxel due to its safer profile. This study evaluates the efficacy and safety of novel polymer-free Amphilimus formulation (Sirolimus + fatty acid) eluting self-expanding stent in the treatment of femoropopliteal disease in a real-world population.
View Article and Find Full Text PDFA Narrative Review of Endovascular Approaches for Chronic Mesenteric Ischemia.
Interv Radiol (Higashimatsuyama)
August 2025
Department of Radiology, Sumitomo Hospital, Japan.
Chronic mesenteric ischemia typically presents with postprandial abdominal pain and weight loss due to atherosclerotic stenosis of mesenteric arteries. Endovascular treatment has become the first-line management, demonstrating lower early mortality and fewer complications compared to open surgery. Recent evidence shows that covered stents provide superior long-term outcomes, with better primary patency and freedom from reintervention than bare-metal stents.
View Article and Find Full Text PDFCatch Up with the Latest Trend in Vascular Access Intervention.
Interv Radiol (Higashimatsuyama)
August 2025
Department of Diagnostic and Interventional Radiology, Nara Medical University, Japan.
Vascular access dysfunction remains a significant challenge in hemodialysis patients, primarily caused by stenosis and occlusion in arteriovenous fistulas and grafts. Recent advancements in percutaneous transluminal angioplasty have introduced innovative tools such as drug-coated balloons and stent grafts. Drug-coated balloons enhance patency by reducing neointimal hyperplasia through localized drug delivery, with superior outcomes demonstrated in randomized controlled trials.
View Article and Find Full Text PDFObjectives: The purpose of this paper was to compare the efficacy of covered stents (CSs) and bare metal stents (BMSs) in treating all types of aortoiliac occlusive disease (AIOD) and subsequently to analyze the risk factors associated with restenosis, limb salvage, and patency.
Methods: This prospective cohort study included consecutive patients with AIOD who underwent aortoiliac angioplasty, and two groups of patients were evaluated: patients with AIOD submitted to endovascular treatment with the use of covered stents and bare metal stents. Patients with critical limb ischemia or incapacitating claudication who underwent aortoiliac angioplasty during the index period were eligible for the study.